BRCA gene mutations are found in up to 10% of pancreatic adenocarcinoma cases. We present a description of 4 cases along with a review of the current literature regarding pathogenesis, target treatment, response and survival rates in these types of malignancies. We describe four cases of pancreatic adenocarcinoma, in three of which the BRCA2 mutation was identified, in one -BRCA1 gene alteration. Two patients underwent surgery following the neoadjuvant treatment with Folfirinox and radiotherapy; in the first case, a distal pancreatectomy with splenectomy was performed and in the second one -the Whipple's procedure. In both cases, a complete pathological response was reported. Other 2 patients were treated with Folfirinox after BRCA mutation identification and acceptable life expectancy was obtained. The association of pathologic complete response (PCR) with lower rates of local recurrence and better survival in patients with various types of adenocarcinomas is well known. Identification of such patients carrying BRCA mutations could provide an application of better personalized treatment. In some patients with pancreatic cancer, especially when there is clinical or demographic reason to suspect a genetic predisposition, a confirmation of the presence of BRCA mutations could provide an opportunity to use target treatment with beneficial outcomes regarding survival. 
INTRODUCTION
The median survival of pancreatic ductal cancer today comprises less than 1 year for advanced stages of the disease, and even when early diagnosed, the 5-year survival for the above malignancy reaches only 7%. 1 Around 10% of the pancreatic ductal adenocarcinoma (PDAC) are associated with hereditary predisposition. 2 BRCA2 mutations increase the risk of breast cancer, prostate cancer, pancreatic cancer, and melanoma and stomach cancer. 3 It is estimated that in BRCA2 carriers, the cumulative risk of all cancers is 32% for men by the age of 70 years, and 90% for women. 4 The estimated lifetime risk of pancreatic cancer for individuals with a BRCA2 mutation is 4.9%. 5 The cases of familial pancreatic cancer (FPC) have also been reported. 6 Researchers have documented germinal gene mutations which are known to increase the risk of PDAC.
The effect of BRCA mutations and response to DNA crosslinking agents in PDA was evaluated and there are authors who reported that BRCA-associated PDA in patients receiving a platinum agent as first-line metastatic therapy demonstrated a partial or complete radiographic response. 7 Lowery et al. 8 have been studying the effect of BRCA mutations and response to DNA crosslinking agents in PDAC. It was reported that 5/6 BRCA-associated PDAC patients who received a platinum agent as first-line metastatic therapy demonstrated a partial or complete radiographic response (Table 1) . This favorable response of people. 5 This rate is generally higher in developed countries and among males remaining at the same level over the past 30 years relative to the incidence of other common solid tumors. 5, 12 It is the eighth leading cause of death from cancer among men and the ninth in women throughout the world. shown that the third most common cancer associated with these mutations is pancreatic cancer. 13 In a prospective study, a statistically significant 2.4-fold increase in pancreatic cancer incidence was found in female BRCA mutation carriers compared with the general population. 14 Women with a BRCA mutation who were over the age of 50 had an annual risk of developing pancreatic cancer of 0.04 percent. If these female BRCA mutation carriers had a first-degree relative with pancreatic cancer, the annual risk for developing pancreatic cancer was 1 percent. should be considered in BRCA mutation carriers. 13 Platinum analogues are DNA cross-linking agents, which kill tumor cells by creating DNA lesions during S-phase, probably inhibiting DNA replication. 9 Regarding the role of BRCA in DNA repair, it is speculated that mutations in BRCA1 and BRCA2 result, on the one hand, in the increased cancer incidence due to defective homologous recombination, which leads to genome instability, but, on the other hand, these cancers are more sensitive to DNA cross-linking agents such as cisplatin or oxaliplatin.
We report 2 cases of pancreatic adenocarcinoma associated with BRCA2 mutations where a good response to the treatment was observed. Similar favorable response of BRCA-associated PDA to DNA crosslinking agents was also reported in a series by Sonnenblick et al. 9 ( Table 1) . 8, 9, [20] [21] [22] [23] A survival advantage under application of platinum-containing regimens was also reported for patients with PDA and a family history of any malignancy, in whom the status of BRCA mutation status was not assessed. 
